Advertisement
Screener

INHIBRX BIOSCIENCES, INC. (INBX) Deferred Tax Liabilities, Gross

1.4 / 5 stars · 5/18 Roast Me

INHIBRX BIOSCIENCES, INC. Deferred Tax Liabilities, Gross

INHIBRX BIOSCIENCES, INC. (INBX) had Deferred Tax Liabilities, Gross of $1.21 million as of 2025-12-31, per its 10-K filed 2026-03-19.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net

us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-19

  • 2025-12-31: Deferred Tax Liabilities, Gross $1.21M.
  • 2024-12-31: Deferred Tax Liabilities, Gross $2.19M.
  • 2023-12-31: Deferred Tax Liabilities, Gross $658.00K.
Period endDeferred Tax Liabilities, Gross
2025-12-31$1.21M
10-K · filed 2026-03-19
2024-12-31$2.19M
10-K · filed 2026-03-19
2023-12-31$658.00K
10-K · filed 2025-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81